Search results
AbbVie raises earnings forecast on strong immunology drug growth
Crain s Chicago Business· 2 days agoThe growth helped offset sales declines of Humira, AbbVie’s once best-selling immunosuppressive medication that began facing biosimilar competition last year. Humira sales ...
REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study
Reuters via Yahoo Finance· 3 days ago(Corrects to remove extraneous text and to add Regeneron ticker symbol) April 25 (Reuters) - AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory ...
AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up
Investing.com· 3 days agoAbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up
AbbVie Lifts Profit Forecast After Skyrizi Sales Beat Expectations
US News & World Report· 2 days agoUS News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AOL· 3 days agoRinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent ...
PCE/Core PCE Numbers Came In Line With Expectations
Zacks via Yahoo Finance· 2 days agoSo while we see progress on inflation having become stagnant — in this and other economic data out this month — these are far from the fearful numbers...
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters via Yahoo Finance· 3 days agoAbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent ...
AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
Morningstar· 2 days agoShares of AbbVie lost 4.6% to close at $159.62 on Friday after the company warned about the effects of losing the exclusivity of its patent for the arthritis medication Humira ...
AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises
Morningstar· 2 days agoBy Dean Seal AbbVie raised its annual adjusted earnings guidance after revenue unexpectedly rose in the first quarter as lower sales of Humira were offset with gains elsewhere ...
AbbVie Reports First-Quarter 2024 Financial Results
The Southern Illinoisan· 2 days agoReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable